SGSU 2012 Annual Meeting
Needs and Objectives
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Oklahoma College of Medicine and the SGSU. The University of Oklahoma College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Oklahoma College of Medicine designates this live activity for a maximum of 24.25 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Conflict Resolution Statement
The University of Oklahoma College Of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and resolved all identified conflicts of interest, if applicable.
Equal Opportunity Statement
The University of Oklahoma is an equal opportunity institution.
General Disclaimer
The statements and opinions contained in this program are solely those of the individual authors and contributors and not of the SGSU. The appearance of the advertisements is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. The content of this publication may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses. The SGSU disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the abstracts or advertisements.
Special Assistance
We encourage participation by all individuals. If you have a disability, advance notification of any special needs will help us better serve you. Call (847) 517-7225 if you require special assistance to fully participate in the meeting.
Overview
Topics featured at the Kimbrough Urologic Seminar will include state-of-the-art discussions in urology. Issues to be addressed by national experts include laparoscopy, reconstructive surgery, pediatrics, general urology, and oncology. Participants at the meeting will learn diagnostic approaches, management strategies, and current treatment options. These new innovations will help government urologists maintain competency in this rapidly evolving field.
In addition, a resident research competition and mock oral board’s preparation for those preparing for Part II of the American Board of Urology certifying examination will be included.
This conference is intended primarily for urologist who serves or has served the federal government in any capacity as an urologist, including active duty, consultants, and residents. The meeting focuses on urologic conditions prevalent in the active duty and veteran populations, and as a venue for government service urologists to share information pertinent to urologic practice on the battlefield.
Needs Assessment
The field of laparoscopy, and more specifically robotics, is rapidly evolving. In this session recent advances to the da Vinci robotic system such as teaching modules will be discussed. Newer surgical techniques and indications for the robotic system will be covered as well. Additionally laparoscopic advances in renal, adrenal, and prostate surgery will be covered.
One of the sessions at this meeting will highlight the challenging problem of urinary incontinence and anastomotic strictures after prostate cancer surgery. This troubling combination has a significant impact on the quality of life of men with prostate cancer. Most urologists are unaware of the risk factors which can lower the incidence of these conditions. Additionally, the treatment of this combination can be complex. Further understanding will allow the urologist to more successfully handle these situations.
The erectile dysfunction session will address the state of the art management of surgery for erectile dysfunction. As our population continues to age more men will suffer from erectile dysfunction. One of the most successful treatments is penile prosthesis surgery. Advances in penile prosthesis surgery have made both their use and surgery easier. Further advances in the technology have also lowered the risk of infections.
The pediatrics session will include an update on what the adult urologist needs to safely care for the pediatric patient. Recently, new guidelines have been published on the treatment of vesicoureteral reflux. Management can consists of observation, antibiotics, or surgical interventions to include endoscopy, laparoscopy, or open approaches. There will also be a discussion regarding the management of cryptorchidism. Timing for this surgery has continued to evolve. Recent evidence has shown not only greater long-term benefits to early intervention but also that after the first several months testicles do not descend. Lastly, the treatment of ureteropelvic junction obstruction will be discussed. Recent evidence has shown benefits to early intervention. The timing and indications for these earlier interventions will be discussed.
The focus of the general urology session will be on priapism and peyronie’s disease. Priapism is one of the true emergencies of urology. As such a urologist may be called at any time to successfully treat this condition. Recently there have been some new techniques to treat priapism. These new techniques make treatment not only easier but also more successful. Additionally new information on the long-term erectile dysfunction after treatment of priapism will be discussed. Peyronie’s disease has become better know in the lay press. As such urologist are more likely to encounter these patients. New treatments including collagenase injections are soon to complete Phase 3 trials and may potentially become available for treatment.
The oncology sessions will explore current topics related to prostate cancer. The diagnosis and treatments of prostate cancer are largely based on Prostate Specific Antigen (PSA) testing. Recently information to both support and counter the use of PSA testing has been reported. The urologist needs to be aware of the advantages and disadvantages of PSA testing and be able to explain to patients how recent literature relates to their individual situation. Additionally, health care costs have been at the forefront of the nation’s budget debate. As these discussions enter medicine, prostate cancer treatments are sure to be discussed. Urologist must be able to understand how the cost of both local and systemic treatments will affect future treatment options. The cost in relation to quality adjusted life years will also be explained to the urologist. Lastly, the use of testosterone supplementation for men with hypogonadism has become more prominent. Traditionally the use of testosterone replacement therapy after prostate cancer has been shunned. New studies have shown that treatment is not only safe but can increase quality of life and reduce the severity of erectile dysfunction. Urologist need to be aware of this new information in order to safely practice testosterone replacement therapy for prostate cancer patients.
Objectives
After attending this meeting, participants should be able to: